# Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia

> **NCT04160260** · PHASE1 · COMPLETED · sponsor: **Paratek Pharmaceuticals Inc** · enrollment: 18 (actual)

## Conditions studied

- Community-acquired Pneumonia

## Interventions

- **DRUG:** Omadacycline

## Key facts

- **NCT ID:** NCT04160260
- **Lead sponsor:** Paratek Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-28
- **Primary completion:** 2020-03-23
- **Final completion:** 2020-04-13
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04160260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04160260, "Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04160260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*